Investigating how maternal characteristics affect child growth and obesity
Official title: Maternal Characteristics Associated With Child Growth and Adiposity. Search for Nutrigenomic Biomarkers in Peripheral Blood
Run by Instituto de Desarrollo e Investigaciones Pediátricas Prof. Dr. Fernando E. Viteri · NCT05798676 · Data updated 2026-11-12
This study looks at how hormone levels in breastfeeding mothers affect their children's growth and risk of obesity.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 40 Years |
| Sex | Women only |
| Enrollment | 130 (estimated) |
| Sponsor | Instituto de Desarrollo e Investigaciones Pediátricas Prof. Dr. Fernando E. Viteri Academic / other |
| Locations | 1 site (La Plata, Buenos Aires) |
| Status | Recruiting |
| Started | May 2, 2019 |
| Main results expected | March 2028 |
| Study ends | March 2028 |
| Registry record updated | December 26, 2025 |
| Trial ID | NCT05798676 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are lactating women with pre-pregnancy normal weight or overweight/obesity.
✕Probably not a fit
Patients with diabetes, multiple pregnancies, hypertensive disorders during pregnancy, or those who delivered pre-term infants will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to explore the relationship between maternal hormone levels and child growth and adiposity. It will analyze concentrations of leptin, insulin, LEAP2, and cortisol in both plasma and breast milk from lactating women with normal weight and those with pre-pregnancy overweight or obesity. Participants will provide milk and blood samples, allowing researchers to compare the hormonal profiles and their associations with infant growth and obesity outcomes. The study seeks to understand how maternal and infant hormones and their receptors influence child development.
Why it matters
Potential benefit: If successful, this study could provide insights into how maternal health impacts child growth and obesity, potentially guiding interventions for at-risk populations.
How similar studies have gone: While similar studies have explored maternal influences on child health, this specific focus on hormonal associations in the context of obesity is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Lactating women with pre-pregnancy normal weight and overweight or obesity as described by the World Health Organization. Exclusion Criteria: * Diabetes (Type I or II or gestational) * Multiple pregnancy * Hypertensive disorders during pregnancy * Delivery of pre-term infant (\<37 weeks).
Where it's running
-
Instituto de Desarrollo e Investigaciones Pediátricas Prof. Dr. Fernando E. Viteri
La Plata, Buenos Aires, Argentina Recruiting
Study contacts
- Principal investigator: Maria F Andreoli, BsC — Instituto de Desarrollo e Investigaciones Pediátricas Prof. Dr. Fernando E. Viteri
- Study coordinator: Maria F Andreoli, PhD
- Email: mfandreoli@gmail.com
- Phone: 54 221 4535901
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Ocular Changes in People Using Tirzepatide or Semaglutide
This study checks whether eye structure and blood vessels change in adults with obesity who are taking semaglutide or tirzepatide as part of routine care.
-
Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes
This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.
-
Berobenatide for knee pain in adults who are overweight or with obesity
This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.
-
Weekly berobenatide for knee osteoarthritis in adults who are overweight or obese
This study tests whether weekly berobenatide helps reduce knee pain and improve function, while also affecting body weight, in adults with knee osteoarthritis who are overweight or obese (with or without type 2 diabetes).
-
Maridebart cafraglutide in people who switched from weekly GLP-1 receptor agonists
This study tests how much maridebart cafraglutide appears in the blood after people with overweight or obesity switch from weekly GLP-1 receptor agonists.
-
EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes
This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.